Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MORDECHAI RABINOVITZ

NPI
1306811864
CMS profile
1303516
Location
PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$35.93

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $35.93 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $35.93 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MORDECHAI RABINOVITZ

NPI 1306811864 · CMS profile ID 1303516

PITTSBURGH, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1306811864?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MORDECHAI RABINOVITZ, NPI 1306811864, CMS profile ID 1303516. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1306811864?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MORDECHAI RABINOVITZ, NPI 1306811864, CMS profile ID 1303516. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1306811864?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MORDECHAI RABINOVITZ, NPI 1306811864, CMS profile ID 1303516, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1306811864?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $35.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $35.9307/07/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891404941 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $14.47 1
PY2022 $35.93 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $191,701.92 80
PY2024 Principal investigator $234,320.46 52
PY2023 Principal investigator $28,632.91 11
PY2022 Principal investigator $26,708.62 15
PY2021 Principal investigator $139,687.05 180
PY2020 Principal investigator $228,284.04 36
PY2019 Recipient $7,883.21 4
PY2019 Principal investigator $215,757.46 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

78 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $72.25 12/31/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721641
Principal investigator 1 Novo Nordisk AS $1,215.45 12/19/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458597
Principal investigator 1 Gilead Sciences, Inc. $1,310.00 12/18/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399355
Principal investigator 1 Novo Nordisk AS $1,620.90 12/03/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458595
Principal investigator 1 Novo Nordisk AS $72.25 11/30/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721637
Principal investigator 1 Gilead Sciences, Inc. $2,620.00 11/20/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399351
Principal investigator 1 Novo Nordisk AS $72.25 10/31/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721639
Principal investigator 1 Novo Nordisk AS $810.45 10/29/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458589
Principal investigator 1 Gilead Sciences, Inc. $8,045.00 10/23/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399345
Principal investigator 1 Novo Nordisk AS $14.97 10/11/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721681
Principal investigator 1 Novo Nordisk AS $32.97 10/11/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721683
Principal investigator 1 Novo Nordisk AS $72.25 09/30/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721643
Principal investigator 1 Novo Nordisk AS $1,955.70 09/26/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458593
Principal investigator 1 Eli Lilly and Company $17,750.00 09/23/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF BARICITINIB (LY3009104) IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WHO HAVE AN INADEQUATE RESPONSE OR ARE INTOLERANT TO UDCA No dispute reported 06/30/2026 654298077
Principal investigator 1 Gilead Sciences, Inc. $1,310.00 09/18/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399341
Principal investigator 1 Novo Nordisk AS $72.25 08/31/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721645
Principal investigator 1 Novo Nordisk AS $6.75 08/30/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721679
Principal investigator 1 Merck Sharp & Dohme Corporation $11.64 08/28/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER
A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and,or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial No dispute reported 06/30/2026 691529499
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $106.40 08/27/2019 Non-covered Recipient Entity
University Of Pittsburgh Medical Center - Center For Liver Disease
Phase IIB Study - F3 24 wk No dispute reported 06/30/2026 639756273
Principal investigator 1 Gilead Sciences, Inc. $3,779.00 08/21/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399337
Principal investigator 1 Novo Nordisk AS $5.10 08/21/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721669
Principal investigator 1 Novo Nordisk AS $14.70 08/21/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721671
Principal investigator 1 Novo Nordisk AS $25.00 08/21/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721673
Principal investigator 1 Novo Nordisk AS $11.38 08/21/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721675
Principal investigator 1 Novo Nordisk AS $2.25 08/21/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721677
Principal investigator 1 AbbVie, Inc. $684.00 08/07/2019 Non-covered Recipient Entity
University Of Pittsburgh Physician
M16-135 No dispute reported 06/30/2026 671841359
Principal investigator 1 Novo Nordisk AS $72.25 07/31/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721647
Principal investigator 1 Novo Nordisk AS $2,598.75 07/30/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458591
Principal investigator 1 Eli Lilly and Company $22.68 07/23/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF BARICITINIB (LY3009104) IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WHO HAVE AN INADEQUATE RESPONSE OR ARE INTOLERANT TO UDCA No dispute reported 06/30/2026 654299011
Principal investigator 1 Gilead Sciences, Inc. $310.00 07/22/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399331
Principal investigator 1 Gilead Sciences, Inc. $1,646.00 07/17/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399325
Principal investigator 1 Eli Lilly and Company $22.68 07/03/2019 Non-covered Recipient Entity
UNIV OF PITTSBURGH CANCER INSTITUTE CANCER SRVCS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF BARICITINIB (LY3009104) IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WHO HAVE AN INADEQUATE RESPONSE OR ARE INTOLERANT TO UDCA No dispute reported 06/30/2026 654296515
Principal investigator 1 Novo Nordisk AS $72.25 06/30/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721635
Principal investigator 1 Novo Nordisk AS $5.10 06/27/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721663
Principal investigator 1 Novo Nordisk AS $6.75 06/27/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721665
Principal investigator 1 Novo Nordisk AS $8.96 06/27/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721667
Principal investigator 1 Eli Lilly and Company $1,317.24 06/25/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF BARICITINIB (LY3009104) IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WHO HAVE AN INADEQUATE RESPONSE OR ARE INTOLERANT TO UDCA No dispute reported 06/30/2026 654298329
Principal investigator 1 Novo Nordisk AS $810.45 06/25/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458587
Principal investigator 1 Gilead Sciences, Inc. $1,310.00 06/19/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399321
Recipient Bausch Health US, LLC $2,100.65 06/12/2019 Covered Recipient Physician A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. No dispute reported 06/30/2026 684338457
Recipient Bausch Health US, LLC $2,100.65 06/12/2019 Covered Recipient Physician A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. No dispute reported 06/30/2026 684338489
Recipient Bausch Health US, LLC $1,581.26 06/12/2019 Covered Recipient Physician A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. No dispute reported 06/30/2026 684338493
Recipient Bausch Health US, LLC $2,100.65 06/12/2019 Covered Recipient Physician A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. No dispute reported 06/30/2026 684338497
Principal investigator 1 Novo Nordisk AS $72.25 05/31/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721631
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $39.37 05/28/2019 Non-covered Recipient Entity
University Of Pittsburgh Medical Center - Center For Liver Disease
Phase IIB Study - F4 48 wk No dispute reported 06/30/2026 639756275
Principal investigator 1 Novo Nordisk AS $1,980.90 05/28/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458585
Principal investigator 1 Gilead Sciences, Inc. $5,425.00 05/22/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399317
Principal investigator 1 Intercept Pharmaceuticals, Inc. $2,860.00 05/13/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
1011386 No dispute reported 06/30/2026 702070697
Principal investigator 1 Novo Nordisk AS $11.38 05/03/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721661
Principal investigator 1 Novo Nordisk AS $72.25 04/30/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721633
Principal investigator 1 Novo Nordisk AS $990.45 04/25/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458583
Principal investigator 1 Gilead Sciences, Inc. $4,266.00 04/17/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399311
Principal investigator 1 Dova Pharmaceuticals $250.00 04/03/2019 Non-covered Recipient Entity
Western Institutional Review Board Inc
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. No dispute reported 06/30/2026 689420757
Principal investigator 1 Intercept Pharmaceuticals, Inc. $200.00 04/03/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
1011386 No dispute reported 06/30/2026 702068531
Principal investigator 1 Novo Nordisk AS $72.25 03/29/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721653
Principal investigator 1 Novo Nordisk AS $2,250.90 03/28/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458581
Principal investigator 1 Gilead Sciences, Inc. $310.00 03/25/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399307
Principal investigator 1 Gilead Sciences, Inc. $2,620.00 03/20/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399302
Principal investigator 1 Novo Nordisk AS $5.10 03/15/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721655
Principal investigator 1 Novo Nordisk AS $17.07 03/15/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721657
Principal investigator 1 Novo Nordisk AS $6.75 03/15/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721659
Principal investigator 1 Janssen Research & Development, LLC $5,378.00 03/04/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ 56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection No dispute reported 06/30/2026 654263881
Principal investigator 1 Novo Nordisk AS $72.25 02/28/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721651
Principal investigator 1 Gilead Sciences, Inc. $4,500.00 02/27/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399297
Principal investigator 1 Novo Nordisk AS $1,125.45 02/26/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458579
Principal investigator 1 Gilead Sciences, Inc. $3,930.00 02/20/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399293
Principal investigator 1 AbbVie, Inc. $700.00 02/19/2019 Non-covered Recipient Entity
University Of Pittsburgh Physician
M16-135 No dispute reported 06/30/2026 671841353
Principal investigator 1 Dova Pharmaceuticals $9,516.00 02/14/2019 Covered Recipient Teaching Hospital
UPMC ST MARGARET
Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding. No dispute reported 06/30/2026 689420625
Principal investigator 1 AbbVie, Inc. $312.50 02/07/2019 Non-covered Recipient Entity
University Of Pittsburgh Physician
M16-135 No dispute reported 06/30/2026 671841355
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $41,886.50 02/05/2019 Non-covered Recipient Entity
University Of Pittsburgh Physicians
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND COMPENSATED LIVER CIRRHOSIS No dispute reported 06/30/2026 639756269
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $70,729.40 02/05/2019 Non-covered Recipient Entity
University Of Pittsburgh Physicians
A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 PEG-FGF21 IN ADULTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND STAGE 3 LIVER FIBROSIS No dispute reported 06/30/2026 639756271
Principal investigator 1 Novo Nordisk AS $72.25 01/31/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 706721649
Principal investigator 1 Gilead Sciences, Inc. $1,310.00 01/28/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 676399287
Principal investigator 1 Merck Sharp & Dohme Corporation $11.64 01/28/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH MEDICAL CENTER
A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and,or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial No dispute reported 06/30/2026 691495415
Principal investigator 1 Novo Nordisk AS $2,637.09 01/24/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458577
Principal investigator 1 Novo Nordisk AS $400.00 01/10/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458573
Principal investigator 1 Novo Nordisk AS $889.44 01/10/2019 Non-covered Recipient Entity
UNIVERSITY OF PITTSBURGH PHYSICIANS
NN9931-4296 No dispute reported 06/30/2026 692458575
Principal investigator 1 AbbVie, Inc. $941.25 01/02/2019 Non-covered Recipient Entity
University Of Pittsburgh Physician
M16-135 No dispute reported 06/30/2026 671841357